Elsevier

Toxicology and Applied Pharmacology

Volume 306, 1 September 2016, Pages 17-26
Toxicology and Applied Pharmacology

Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model

https://doi.org/10.1016/j.taap.2016.06.026Get rights and content

Highlights

  • Diminazene aceturate (DIZE), an ACE2 activator prevents ovalbumin-induced asthma.

  • DIZE acted by upregulating ACE2, downregulating ACE1, MAPKs, markers of inflammation, apoptosis.

  • DIZE reduced airway inflammation, fibrosis, right ventricular hypertrophy and restored airway responsiveness.

Abstract

Angiotensin-I converting enzyme (ACE) is positively correlated to asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS) and is highly expressed in lungs. ACE2, the counteracting enzyme of ACE, was proven to be protective in pulmonary, cardiovascular diseases. In the present study we checked the effect of ACE2 activation in animal model of asthma. Asthma was induced in male wistar rats by sensitization and challenge with ovalbumin and then treated with ACE2 activator, diminazene aceturate (DIZE) for 2 weeks. 48 h after last allergen challenge, animals were anesthetized, blood, BALF, femoral bone marrow lavage were collected for leucocyte count; trachea for measuring airway responsiveness to carbachol; lungs and heart were isolated for histological studies and western blotting. In our animal model, the characteristic features of asthma such as altered airway responsiveness to carbachol, eosinophilia and neutrophilia were observed. Western blotting revealed the increased pulmonary expression of ACE1, IL-1β, IL-4, NF-κB, BCL2, p-AKT, p-p38 and decreased expression of ACE2 and IκB. DIZE treatment prevented these alterations. Intraalveolar interstitial thickening, inflammatory cell infiltration, interstitial fibrosis, oxidative stress and right ventricular hypertrophy in asthma control animals were also reversed by DIZE treatment. Activation of ACE2 by DIZE conferred protection against asthma as evident from biochemical, functional, histological and molecular parameters. To the best of our knowledge, we report for the first time that activation of ACE2 by DIZE prevents asthma progression by altering AKT, p38, NF-κB and other inflammatory markers.

Introduction

Asthma is a chronic inflammatory disorder of the airways in which different cell types, in particular mast cells, eosinophils, T lymphocytes, neutrophils play a critical role (Nicklas, 1997, Patel, 2014). Asthma is a major cause of chronic morbidity and mortality throughout the world and its prevalence increased considerably over the past 20 years, especially in children (Stevenson and Birrell, 2011, Nagai, 2012, Ezeamuzie et al., 2014). Asthma is a condition characterized by persistent or recurrent airway inflammation, airway hyper-responsiveness (AHR), chronic airway remodeling and various degrees of reversible airflow limitation (Bousquet et al., 2000, Nials and Uddin, 2008, Blume and Davies, 2013). Airway remodeling means persistent changes in airway structure including sub-basement fibrosis, mucus hypersecretion, injury to epithelial cells, smooth muscle hypertrophy and angiogenesis (Global Initiative for asthma Guidelines (GINA), National Asthma Education and Prevention Program (NAEPP), 2007) (DiGiovanni et al., 2009).

The renin angiotensin system (RAS) has been widely implicated in the pathophysiology of cardiovascular disorders. RAS operates via two counteracting arms - ACE1/Ang II/AT1 axis and ACE2/Ang-(1-7)/Mas axis. ACE1 produces Ang II which causes vasoconstriction, proliferation, fibrosis, and inflammation through the activation of the AT1 receptor (Shenoy et al., 2013). ACE2 is major Ang-(1-7)-forming enzyme as it converts Ang II to Ang-(1-7) with 500 folds greater affinity. Ang (1-7) is endogenous ligand for the G protein-coupled receptor Mas and promotes vasodilatation, anti-proliferation, baroreflex sensitivity, potentiation of bradykinin activity and AT1 receptor antagonism (Warner et al., 2007). RAS plays a critical role in pathogenesis of pulmonary hypertension, pulmonary fibrosis in chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS) (Kuba et al., 2006, Kaparianos and Argyropoulou, 2011). An increased expression of ACE2 and Ang-(1-7) with ACE1 inhibitors (ACEi) or Angiotensin receptor blockers (ARBs) indicates their beneficial role in degrading Ang II locally (Ferreira et al., 2010). ACE2 knockout worsened bleomycin – induced acute lung injury and rhACE2 abrogated it (Rey-Parra et al., 2012). Taken together, ACE2 might be a potential target for the treatment of asthma.

Diminazene aceturate (DIZE) is the most commonly used therapeutic agent for trypanosomiasis in domestic livestock. It is thought to inhibit DNA replication and mitochondrial type II topoisomerases, but as an off-target effect, it increases the activity of the ACE2-mediated angiotensin conversion and this is considered the actual mechanism behind its beneficial effects (Kulemina and Ostrov, 2011). DIZE treatment has been shown to prevent pulmonary hypertension (Shenoy et al., 2013). Here we have hypothesized that the activation of the protective arm of the RAS by novel ACE2 activator — DIZE may attenuate various characteristics of asthma in rat asthma model.

Section snippets

Animals

All the experiments were performed on male adult Wistar rats (200–260 g; 8–9 weeks old). The animals were procured from Central Animal Facility, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, India. The housing of the animals was done as three animals per cage in a room with controlled ambient temperature (22 ± 2 °C), humidity 50 ± 10% and 12 h light/dark cycle. Feed (Pranav Agro Industries, New Delhi) and water were provided ad libitum. All experimental protocols

Statistical analysis

All the data were expressed as mean ± SEM. Means of all groups were compared by one-way analysis of variance (ANOVA) followed by the Tukey's post-test, unless otherwise specified, using GraphPad Prism (v5.01) (GraphPad Software, Inc., CA, USA). The level of significance was set to P < 0.05.

Diminazene aceturate improves morphometry

As compared with control rats, significant loss in body weight was observed in ovalbumin sensitized and challenged (asthmatic) rats. This loss in body weight was prevented by treatment with diminazene aceturate (DIZE). As compared to control rats, asthmatic rats showed significant increase in lungs to body weight ratio and treatment of asthmatic rats with DIZE restored lungs to body weight ratio and prevented airway remodelling. Though absolute heart weight decreased in asthma rats, relative

Discussion

In the present study, we provide evidence that diminazene aceturate (DIZE), an ACE2 activator, corrects the airway inflammation, remodelling, obstruction and responsiveness associated with asthma. The characteristic features of asthma are airway hyperresponsiveness (AHR), eosinophilia, edema, increased mucus production, bronchial inflammation and increased immunoglobulin E levels (Tipnis et al., 2000). Along with the eosinophils and mast cells, T helper type-2 (TH2) cells also contribute to

Conflict of interest

The authors declare no conflicts of interest.

Disclosure statement

The authors have nothing to disclose

Transparency document

Transparency document.

Acknowledgements

We wholeheartedly thank National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, India for funding and providing all the amenities for carrying out this research work.

References (46)

  • H. Nagai

    Recent research and developmental strategy of anti-asthma drugs

    Pharmacol. Ther.

    (2012)
  • C.S. Stevenson et al.

    Moving towards a new generation of animal models for asthma and COPD with improved clinical relevance

    Pharmacol. Ther.

    (2011)
  • K. Tikoo et al.

    Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: potential role of tannins in cancer chemotherapy

    Toxicol. Appl. Pharmacol.

    (2011)
  • S.R. Tipnis et al.

    A human homolog of angiotensin-converting enzyme cloning and functional expression as a captopril-insensitive carboxypeptidase

    J. Biol. Chem.

    (2000)
  • M.G. Belvisi et al.

    Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma

    J. Pharmacol. Exp. Ther.

    (2005)
  • J. Bousquet et al.

    Asthma: from bronchoconstriction to airways inflammation and remodeling

    Am. J. Respir. Crit. Care Med.

    (2000)
  • A.M. Bramley et al.

    Collagenase increases shortening of human bronchial smooth muscle in vitro

    Am. J. Respir. Crit. Care Med.

    (1995)
  • D.S. Bundschuh et al.

    In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor

    J. Pharmacol. Exp. Ther.

    (2001)
  • Y.S. Cho et al.

    alpha-Lipoic acid inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma

    J. Allergy Clin. Immunol.

    (2004)
  • F.A. DiGiovanni et al.

    Concurrent dual allergen exposure and its effects on airway hyperresponsiveness, inflammation and remodeling in mice

    Dis. Model. Mech.

    (2009)
  • A.Z. El-Hashim et al.

    Angiotensin-(1–7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2-and NF-κB-dependent pathways

    Br. J. Pharmacol.

    (2012)
  • C.I. Ezeamuzie et al.

    Anti-Allergic and anti-asthmatic effects of a novel enhydrazinone ester (CEE-1): inhibition of activation of both mast cells and eosinophils

    J. Pharmacol. Exp. Ther.

    (2014)
  • A.J. Ferreira et al.

    Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases

    Hypertension

    (2010)
  • Cited by (0)

    View full text